Share on StockTwits

Analysts at Brean Capital increased their price target on shares of Ohr Pharmaceutical (OTC:OHRP) from $21.00 to $34.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock.

Ohr Pharmaceutical (OTC:OHRP) traded down 5.56% during mid-day trading on Wednesday, hitting $7.31. 2,235,844 shares of the company’s stock traded hands. Ohr Pharmaceutical has a 1-year low of $5.65 and a 1-year high of $20.00. The stock has a 50-day moving average of $8.66 and a 200-day moving average of $10.9. The company’s market cap is $172.6 million.

Ohr Pharmaceutical Inc (OTC:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.